NCT02472535 - Study to Evaluate the Effects of MBX-8025 in Patients With HoFH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

OTHER

Run-In Period: Placebo

2 capsules, once a day for two weeks

DRUG

MBX-8025 50 mg (Dose Escalation Period 1)

"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"

DRUG

MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)

"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"

DRUG

MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)

"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"

Trial Locations (5)

Ecogene-21, Chicoutimi

Montreal Heart Institute, Montreal

Endocrinologie metabolisme et prevention cardiovasulaire, Institut E3M et IHU cardiometabolique (ICAN), Hôpital Pitié Salpêtrière, Paris

Radbound UMC, Nijmegen

Lipidklinikken, Oslo Universitetssykehus, Oslo